Proprietary AI analyst is now available

Farmacosmo Valuation Multiples

Discover Farmacosmo's revenue and EBITDA valuation multiples and investment history, alongside public comparables like MOGU, Westwing Brasil, MERLIN GROUP, Adore Beauty and more.

Farmacosmo Overview

About Farmacosmo

Farmacosmo SpA is a wellness e-commerce company active in the Health, Pharma, and Wellness industry, authorized by the Italian Ministry of Health to sell pharmaceutical products online.  In particular, the company offers parapharmaceutical products, vitamins and food supplements, dietetic products, medical devices, cosmetic products, personal hygiene products, hair care products, dental care products, skincare products, perfumes, home and baby items.


Founded

2013

HQ

Italy

Employees

N/A

Financials (FY)

Revenue: $65M
EBITDA: $409K

EV

$26M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Farmacosmo Financials

Farmacosmo reported last fiscal year revenue of $65M and EBITDA of $409K.

In the same fiscal year, Farmacosmo generated $17M in gross profit, $409K in EBITDA, and had net loss of ($5M).


Farmacosmo P&L

In the most recent fiscal year, Farmacosmo reported revenue of $65M and EBITDA of $409K.

Farmacosmo is unprofitable as of last fiscal year, with gross margin of 27%, EBITDA margin of 1%, and net margin of (8%).

See analyst estimates for Farmacosmo
Last FY202320242025202620272028
Revenue$65M$83M$74M$65M
Gross Profit$17M$18M$19M$17M
Gross Margin27%22%26%27%
EBITDA$409K($471K)$846K$409K
EBITDA Margin1%(1%)1%1%
EBIT Margin(10%)(4%)(3%)(10%)
Net Profit($5M)($4M)($3M)($5M)
Net Margin(8%)(5%)(5%)(8%)
Net Debt$8M---

Financial data powered by Morningstar, Inc.

Farmacosmo Stock Performance

Farmacosmo has current market cap of $18M, and enterprise value of $26M.

Market Cap Evolution


Farmacosmo's stock price is $0.47.

Farmacosmo share price increased by 0.1% in the last 30 days, and decreased by 19.8% in the last year.

Farmacosmo has an EPS (earnings per share) of $-0.13.

See more trading valuation data for Farmacosmo
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$26M$18M4.5%0.1%-13.2%-19.8%$-0.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Farmacosmo Valuation Multiples

Farmacosmo trades at 0.4x EV/Revenue multiple, and 63.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Farmacosmo

Farmacosmo Financial Valuation Multiples

As of June 18, 2026, Farmacosmo has market cap of $18M and EV of $26M.

Farmacosmo has a P/E ratio of (3.6x).

Last FY202320242025202620272028
EV/Revenue0.4x0.3x0.4x0.4x
EV/EBITDA63.6x(55.3x)30.8x63.6x
EV/EBIT(4.1x)(7.4x)(10.9x)(4.1x)
EV/Gross Profit1.5x1.4x1.3x1.5x
P/E(3.6x)(4.9x)(5.3x)(3.6x)
EV/FCF(10.4x)(3.2x)(6.7x)(10.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Farmacosmo Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Farmacosmo Margins & Growth Rates

In the most recent fiscal year, Farmacosmo reported gross margin of 27%, EBITDA margin of 1%, and net margin of (8%).

See estimated margins and future growth rates for Farmacosmo

Farmacosmo Margins

Last FY20242025202720282029
Gross Margin27%26%27%
EBITDA Margin1%1%1%
EBIT Margin(10%)(3%)(10%)
Net Margin(8%)(5%)(8%)
FCF Margin(4%)(5%)(4%)

Farmacosmo Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(11%)(12%)
Gross Profit Growth5%(11%)
EBITDA Growth(280%)(52%)
EBIT Growth(32%)166%
Net Profit Growth(8%)49%
FCF Growth(53%)(36%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Farmacosmo Operational KPIs

Access forward-looking KPIs for Farmacosmo
Last FY202320242025202620272028
Opex to Revenue36%26%30%36%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Farmacosmo Competitors

Farmacosmo competitors include MOGU, Westwing Brasil, MERLIN GROUP, Adore Beauty, Bubbleroom, Digital Brands Group, Rise, Laxus Technologies, Natural Health Trends and Pilulka Lekarny.

Most Farmacosmo public comparables operate across Consumer E-commerce, Pharmacies, Vertical E-commerce and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
MOGU(2.1x)-6.9x-
Westwing Brasil(0.0x)-(0.8x)-
MERLIN GROUP----
Adore Beauty0.2x0.2x6.0x10.9x
Bubbleroom0.4x-(14.6x)-
Digital Brands Group----
Rise5.6x4.9x20.5x-
Laxus Technologies0.9x1.1x2.7x-

This data is available for Pro users. Sign up to see all Farmacosmo competitors and their valuation data.

Start Free Trial

Investments by Farmacosmo

Farmacosmo has invested in 1 company to date.

Latest investment by Farmacosmo was on November 12th 2025. Farmacosmo invested in 2Watch in their Undisclosed stage round.

See VC round multiples

Latest Investments by Farmacosmo

2Watch
Description
2Watch is a marketing and software development firm based in Los Angeles, California. It builds Twitch channels, proprietary streaming apps, and creator networks for esports and entertainment. Services include ad campaigns on YouTube and TikTok alongside custom game integrations. Founded in 2021, 2Watch supports over 100 content creators with analytics dashboards.
HQ CountryItaly
HQ City
-
Deal Date12 Nov 2025
RoundUndisclosed stage
Raisedundisclosed
InvestorsAlessandro Avallone; Donatello Bianco; Fabio Lalli; Farmacosmo; Francesco Norcia; Luca La Mesa; Massimo Petrella; Pathfinder; SideAngels; Stefano Bassi
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Farmacosmo investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Farmacosmo

When was Farmacosmo founded?Farmacosmo was founded in 2013.
Where is Farmacosmo headquartered?Farmacosmo is headquartered in Italy.
Is Farmacosmo publicly listed?Yes, Farmacosmo is a public company listed on Borsa Italiana.
What is the stock symbol of Farmacosmo?Farmacosmo trades under COSMO ticker.
When did Farmacosmo go public?Farmacosmo went public in 2022.
Who are competitors of Farmacosmo?Farmacosmo main competitors include MOGU, Westwing Brasil, MERLIN GROUP, Adore Beauty, Bubbleroom, Digital Brands Group, Rise, Laxus Technologies, Natural Health Trends, Pilulka Lekarny.
What is the current market cap of Farmacosmo?Farmacosmo's current market cap is $18M.
What is the current revenue of Farmacosmo?Farmacosmo's last fiscal year revenue is $65M.
What is the current EV/Revenue multiple of Farmacosmo?Current revenue multiple of Farmacosmo is 0.4x.
Is Farmacosmo profitable?No, Farmacosmo is not profitable.
How many companies Farmacosmo has acquired to date?Farmacosmo hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Farmacosmo has invested to date?As of June 2026, Farmacosmo has invested in 1 company.
What was the last Farmacosmo investment?On 12th November 2025 Farmacosmo invested in 2Watch, participating in a Undisclosed stage round, alongside Alessandro Avallone, Donatello Bianco, Fabio Lalli, Francesco Norcia, Luca La Mesa, Massimo Petrella, Pathfinder, SideAngels, and Stefano Bassi.
In what companies Farmacosmo invested in?Farmacosmo invested in 2Watch.

See public comps similar to Farmacosmo

Lists including Farmacosmo

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial